Atovaquone
FDA-approved product (tablet, oral), marketed as Atovaquone, Mepron.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Amebiasis
- Malaria
- Pneumocystosis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other agents against amoebiasis and other protozoal diseases
- FDA pharmacologic class
- Antimalarial; Antiprotozoal FDA label ↗
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01AX06; FDA class Antimalarial; FDA class Antiprotozoal
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA30.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli14.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae12.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis56.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Atovaquone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children
NCT00000811
Registered record
- Registry ID
- NCT00000811
- Conditions
- Bacterial Infections; Pneumonia, Pneumocystis Carinii; HIV Infections
- Interventions
- Azithromycin; Atovaquone; Sulfamethoxazole-Trimethoprim
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- Not recorded
- Completion
- 2001-11
- Enrolment
- 690
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBacterial Infections; Pneumonia, Pneumocystis Carinii; HIV InfectionsInterventionAzithromycin; Atovaquone; Sulfamethoxazole-TrimethoprimPhasePhase 2Registry statusCompletedA Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine
NCT00001994
Registered record
- Registry ID
- NCT00001994
- Conditions
- Toxoplasmosis, Cerebral; HIV Infections
- Interventions
- Atovaquone
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionToxoplasmosis, Cerebral; HIV InfectionsInterventionAtovaquonePhaseNot applicableRegistry statusCompletedA Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole
NCT00001996
Registered record
- Registry ID
- NCT00001996
- Conditions
- Pneumonia, Pneumocystis Carinii; HIV Infections
- Interventions
- Atovaquone; Pentamidine isethionate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPneumonia, Pneumocystis Carinii; HIV InfectionsInterventionAtovaquone; Pentamidine isethionatePhasePhase 2Registry statusCompletedA Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX
NCT00002340
Registered record
- Registry ID
- NCT00002340
- Conditions
- Pneumonia, Pneumocystis Carinii; HIV Infections
- Interventions
- Atovaquone; Pentamidine isethionate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 615
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPneumonia, Pneumocystis Carinii; HIV InfectionsInterventionAtovaquone; Pentamidine isethionatePhasePhase 3Registry statusCompletedOtotoxicity of Artemether / Lumefantrine (Coartem) and Other Antimalarials
NCT00451139
Registered record
- Registry ID
- NCT00451139
- Conditions
- Malaria
- Interventions
- artemether/lumefantrine; quinine; atovaquone/proguanil
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMalariaInterventionartemether/lumefantrine; quinine; atovaquone/proguanilPhasePhase 4Registry statusCompleted